All of the following are characteristics of blood donations and transfusions that enable their extensive use for transplantation purposes except _____.
a. individuals can donate on a regular basis without any deleterious effects
b. erythrocytes do not express MHC class I or class II molecules
c. the blood components only need to function for a few weeks
d. only the ABO antigens need to be compatible between donor and recipient
e. blood transfusion is a straight forward and inexpensive process
d. only the ABO antigens need to be compatible between donor and recipient
a. A and B antigens and Rhesus D antigen
b. O antigens
c. MHC class I molecules
d. MHC class II molecules
e. None of the above
a. A and B antigens and Rhesus D antigen
a. the presence or absence of fucose in glycolipids
b. differences in the oligosaccharide attached to the lipid ceramide
c. structural polymorphisms in the Rhesus D antigen the levels of MHC class I and class II molecules.
d. differences in the peptide attached to the lipid ceramide
b. differences in the oligosaccharide attached to the lipid ceramide
a. Acute rejection
b. Chronic rejection
c. Graft-versus-host disease (GVHD)
d. Serum sickness
e. Hyperacute rejection
c. Graft-versus-host disease (GVHD)
a. are specific for HLA class I and class II antigens
b. cause hyperacute rejection
c. cause acute rejection
d. target endothelium for attack by NK cells
e. are IgA and do not fix complement
b. cause hyperacute rejection
a. O - : AB +
b. O + : AB -
c. AB + : O -
d. A + : A -
e. AB - : O +
a. O - : AB +
a. donor T cells with allogeneic HLA molecule on recipient dendritic cells; recipient T cells with allogeneic HLA molecules on donor dendritic cells
b. recipient T cells with allogeneic HLA molecules on donor dendritic cells; donor T cells with allogeneic HLA molecule on recipient dendritic cells
c. recipient T cells with allogeneic HLA molecules on donor dendritic cells; recipient T cells with peptides of allogeneic HLA molecules on recipient dendritic cells
d. recipient T cells with peptides of allogeneic HLA molecules on recipient dendritic cells; donor T cells with peptides of allogeneic HLA molecules on donor dendritic cells
c. recipient T cells with allogeneic HLA molecules on donor dendritic cells; recipient T cells with peptides of allogeneic HLA molecules on recipient dendritic cells
a. Rabbit anti-thymocyte globulin (rATG)
b. Tacrolimus
c. Alemtuzumab
d. Belatacept
e. Basiliximab
c. Alemtuzumab
a. inhibition of inflammation: prednisone
b. inhibition of co-stimulation: daclizumab
c. inhibition of cytokine signaling: basiliximab
d. inhibition of calcineurin: tacrolimus (FK506)
e. inhibition of T-cell proliferation: azathioprine
b. inhibition of co-stimulation: daclizumab
a. thalassemia major
b. Wiskott-Aldrich syndrome
c. Falcon anemia
d. cirrhosis of the liver
e. sickle-cell anemia
d. cirrhosis of the liver
a. Myeloablation
b. Engraftment
c. Relapse
d. Graft-vesus-leukemia
e. Chemotherapy
b. Engraftment
a. acute host-versus-graft disease
b. hyperacute rejection
c. chronic rejection
d. acute graft-versus-host disease
e. cancer
d. acute graft-versus-host disease
a. Natural killer cells
b. Mature T cells
c. Dendritic cells
thymocytes
Mature B cells
b. Mature T cells
a. mature T cell
b. antibody
c. tumor cell
d. dendritic cell
e. NK cell
c. tumor cell
a. CD3
b. the same major histocompatibility antigens as the recipient
c. the same minor histocompatibility antigens as the recipient
d. the same inhibitory KIR receptors as the recipient
e. CD34
e. CD34
a. T cells develop in the male thymus that are not tolerant to minor histocompatibility antigens expressed by the sister
b. mature T cells in the graft have specificity for male-specific minor histocompatibility antigens
c. there are differences between the sexes in how self proteins are modified post-translationally
d. NK-cell alloreactions occur
e. residual female hormones in the graft cause upregulation of HLA class I on male dendritic cells presenting minor histocompatibility antigens
b. mature T cells in the graft have specificity for male-specific minor histocompatibility antigens
a. autologous
b. HLA-matched
c. haploidentical
d. chimeric
e. cross-matched
c. haploidentical
a. Type I hypersensitivity involving anaphylaxis.
b. Type II hypersensitivity leading to hemolytic anemia.
c. Type III hypersensitivity caused by immune complex deposition in blood vessels.
d. Type IV hypersensitivity involving CD8 T-cell cytotoxicity.
e. Type II hypersensitivity leading to thrombocytopenia
c. Type III hypersensitivity caused by immune complex deposition in blood vessels.
a. xenoantigens
b. immunoantigens
c. alloantigens
d. Histoantigens
e. autoantigens
c. alloantigens
a. mature T lymphocytes from the donor mounting an immune response against tissue of the recipient
b. mature T lymphocytes from the recipient mounting an immune response against tissue of the donor
c. mismatching A, B, and O antigens between donor and recipient
d. mismatching Rhesus antigen between donor and recipient
e. antibodies of the donor stimulating NK cell antibody-dependent cell-mediated cytotoxicity (ADCC) of tissues of the recipient
a. mature T lymphocytes from the donor mounting an immune response against tissue of the recipient
a. The bone marrow transplant contains enough mature T cells to reconstitute the recipient and the recipient provides the antigen-presenting cells.
b. The recipient s MHC molecules mediate positive selection of thymocytes in the thymus that interact with donor-derived MHC molecules in the periphery.
c. Reconstituted T cells are restricted by donor, not recipient, HLA allotypes.
d. Without an HLA match, the donor-derived thymocytes undergo negative selection.
e. If the donor is not HLA matched, the reconstituted T cells will be autoreactive.
b. The recipient s MHC molecules mediate positive selection of thymocytes in the thymus that interact with donor-derived MHC molecules in the periphery.
a. T-cell depletion will remove alloreactive T cells from the donor and prevent the potential for graft-versus-host disease (GVHD)
b. mature T-cell chimerism is required to establish long-term tolerance
c. because Don is HLA-haploidentical and male, there is no risk of alloreactivity toward major or minor histocompatibility antigens
d. because of Don s age, the expected bone marrow harvest is already marginal for successful engraftment, and depletion measures would compromise the yield of stem cells
e. the benefit of using a cocktail of immunosuppressive drugs outweighs the risk of contaminating the bone marrow during T-cell depletion
a. T-cell depletion will remove alloreactive T cells from the donor and prevent the potential for graft-versus-host disease (GVHD)
a. A: 0301/0201; B: 4402/0801; DRB1: 0301/0403
b. A: 0301/2902; B: 1801/0801; DRB1: 0301/0701
c. A: 2902/0201; B: 0702/0801; DRB1: 0301/13011
d. A: 0101/0101; B: 5701/0801; DRB1: 0701/0701
e. A: 0101/0301; B: 0702/5701; DRBA: 0403/0301
d. A: 0101/0101; B: 5701/0801; DRB1: 0701/0701
149. What type of hypersensitivity reaction would result from a mismatched blood transfusion? \: a. Type I b. Type II c. Type III d. Type IV
b. Type II